Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC).

Capdevila, Jaume; Martínez‐Trufero, Javier; Dalmau, E.; Álvarez-Escolá, Cristina; Beltrán, Miguel; Durán, Manuel; Gallegos, Isabel; Manzano, José Luís; Mesı́a, Ricard; Pajares, Isabel; Pradera, José Fuentes; Grau, Juan J.; Reig, Òscar; Trigo, J.M.; Grande, Enrique

doi:10.1200/jco.2014.32.15_suppl.e17015

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge this is the first time that resistance to sequential antiangiogenic MKI therapy in advanced thyroid cancer is suggested. This hypothesis has not been reported with other MKIs in clinical trials (13,14,15,16,17) or in clinical practice (18,19). Furthermore, the pivotal phase III study of axitinib in RCC also showed in the subgroup analyses that PFS was significantly shorter in those patients treated with axitinib after progression to sunitinib compared with those who received axitinib after progression to cytokines (20).…”

Section: Discussionmentioning

confidence: 86%

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

Capdevila

Trigo

Aller

et al. 2017

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 86%

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

Capdevila

Trigo

Aller

et al. 2017

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 86%

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).

Capdevila

Pérez

Aller

et al. 2014

JCO

View full text Add to dashboard Cite

Background: Axitinib, an antiangiogenic multikinase inhibitor (MKI), was evaluated in the compassionate use programme (CUP) in Spain (October 2012-November 2014. Subjects and Methods: 47 patients with advanced radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC, n = 34) or medullary thyroid cancer (MTC, n = 13) with documented disease progression were treated with axitinib 5 mg b.i.d. The primary efficacy endpoint was objective response rate (ORR) by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. Progression-free survival (PFS) and adverse events (AEs) were secondary objectives. Regulatory authorities validated the CUP, and all patients signed informed consent form. Results: Axitinib was administered as first-line therapy in 17 patients (36.2%), as second-line in 18 patients (38.3%) and as third/fourth-line in 12 patients (25.5%). With a median follow-up of 11.5 months (0-24.3), ORR was 27.7% (DTC: 29.4% and MTC: 23.1%) and median PFS was 8.1 months (95% CI: 4.1-12.2) (DTC: 7.4 months (95% CI: 3.1-11.8) and MTC: 9.4 months (95% CI: 4.8-13.9)). Better outcomes were reported with first-line axitinib, with an ORR of 53% and a median PFS of 13.6 months compared with 16.7% and 10.6 months as second-line treatment. Twelve (25.5%) patients required dose reduction to 3 mg b.i.d. All-grade AEs included asthenia (53.2%), diarrhoea (36.2%), hypertension (31.9%) and mucositis (29.8%); grade 3/4 AEs included anorexia (6.4%), diarrhoea (4.3%) and cardiac toxicity (4.3%). Conclusion: Axitinib had a tolerable safety profile and clinically meaningful activity in refractory and progressive thyroid cancer regardless of histology as first-line therapy. To our knowledge, this is the first time that cross-resistance between MKIs is suggested in thyroid cancer, highlighting the importance of prospective sequential clinical studies.

show abstract

Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC).

Cited by 2 publications

References 0 publications

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).

Contact Info

Product

Resources

About